News >

EMA to Review Olaparib in BRCA-mutated, HER2-negative Breast Cancer

Jason Harris
Published: Tuesday, Apr 03, 2018

breast cancer
The European Medicines Agency has accepted a marketing authorization application for olaparib (Lynparza) to treat women with BRCA-mutated, HER2-negative metastatic breast cancer who previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.

Merck (MSD) noted in a press release that this is the first time an approval has been sought in Europe for a PARP inhibitor in breast cancer. The company entered an agreement with AstraZeneca in July 2017 to jointly develop olaparib. The US FDA approved olaparib in this setting based on the same data in January of this year.
Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. 2017;377:523-33. N Engl J Med. doi: 10.1056/NEJMoa1706450.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication